hypertrophic (4), abnormally branched (5), or ectopically located notochord (1) .
Both the digestive and respiratory systems derive from a common embryonic organ, the foregut. The respiratory system originates from an endodermal diverticulum in the ventral wall of the foregut whereas the esophagus derives from the dorsal wall. Because of this common origin, abnormal play of the factors that modulate the development often results in structural anomalies involving both systems (6) .
The inductive activity of the notochord is mediated by the morphogene Sonic hedgehog (Shh). The Hh pathway regulates foregut development and lung morphogenesis through specific and dynamic epithelial-mesenchymal interactions and the Shh signal is initially expressed in the notochord, foregut, and ventral part of the neural tube (1) . The Shh gene encodes a secreted intercellular signaling polypeptide that binds to a transmembrane receptor complex comprising two components: Patched (Ptch), a negative regulator, and Smoothened (Smo), a positive transducer of Shh signaling. Shh binding to Ptch releases Smo that will activate three zinc finger transcription factors Gli1, Gli2, and Gli3 that regulate the transcription of Shh-responsive target genes (7) . In studies with Shh pathway mutant mice, the spectrum of foregut malformations ranges from esophageal and tracheal stenosis and lung dysplasia to esophageal atresia and tracheoesophageal fistula with severe lung hypoplasia; moreover, the disturbance in Shh signal transduction as seen in Gli2 − / − ; Gli3 + / − mice results in a similar Shh − / − phenotype whereas Gli2 − / − ; Gli3 − / − mice present more severe characteristics illustrating the importance of gene dosage in the Shh pathway during foregut development (7, 8) .
In the adriamycin toxicologic model of esophageal atresia, the ectopic localization of the notochord induced by adriamycin leads to disruption in Shh signaling in the prospective site of tracheoesophageal separation in the rat embryo (1, 9) . Moreover, the level of Shh protein expression in the foregut is much lower than in control embryos and does not show timedependent changes (10) . Shh expression in the mouse respiratory primordium has an important role in lung branching and its misexpression results in severe alveolar hypoplasia and a significant increase in lung mesenchyme (11) .
In the human condition this implication is still speculative. Nevertheless, mutations/deletions affecting FOXF1, which is linked to Shh signaling, and mutation of HOXD13, a downstream target of Shh, result in a VACTERL-like phenotype (12) ; furthermore, several human syndromic esophageal atresias implicate deletions/mutations in genes that also seem to interact with the Shh pathway as MYCN (Feingold syndrome) (13, 14) , SOX2 (anophthalmia-esophageal-genital syndrome) (15, 16) , Mid1 (X-linked Opitz syndrome) (17, 18) , and Gli3 (Pallister-Hall syndrome) (19, 20) . These reported genetic disorders suggest that disturbances of Shh signaling due to interacting pathways may play a role in the EA-TEF/VACTERL association phenotype. Along with the gastrointestinal phenotype, defects in signaling via Shh are associated with pulmonary malformations such as lung hypoplasia of varying levels of severity as seen in Pallister-Hall and Smith-Lemli-Opitz syndromes or in the VACTERL association itself (21) .
Adriamycin-induced EA-TEF is associated with defective tracheobronchial branching and some degree of lung hypoplasia (22, 23) . The present study examined whether the abnormal foregut expression pattern of Shh at the site of emergence of the tracheobronchial bud is translated into the developing lung of rats with EA-TEF/VACTERL association. For this purpose, the messenger RNA of several components of the cascade genes involved in Shh regulation was measured by real-time reverse transcription polymerase chain reaction (RT-PCR) and their respective proteins were immunolocalized in the lungs at specific time endpoints, embryonic days 13, 15, 18, and 21 (E13, E15, E18, and E21) corresponding to the late embryonic, pseudoglandular, canalicular, and saccular stages of lung development.
RESULTS

Lung Mass at the Embryonic Stage of Development
Adriamycin-exposed rats had smaller lungs than controls, and this feature was more marked in those with EA-TEF. This is depicted in Figure 1 .
Messenger RNA Expression of Genes of the Shh Signaling Pathway
These results are shown in Figures 2-6 .
E13 (Late Embryonic Stage)
The lungs of rat embryos with EA-TEF induced by adriamycin exhibited significantly lower levels of mRNA of all studied components of the Shh signaling pathway. In contrast, the lungs of adriamycin-exposed embryos without EA-TEF showed the highest mRNA levels except for Ptch. Shh mRNA expression at the late embryonic, pseudoglandular, canalicular, and saccular stages of lung development. Lungs from adriamycin-exposed with EA-TEF (esophageal atresia and tracheoesophageal fistula) fetuses showed a significantly lower expression in contrast to the adria noEA group that exhibited the highest levels, at E13 (white bars). From E13 onwards, Shh mRNA was overexpressed by both adriamycinexposed lungs with the exception of adria noEA at E21 (hatched bars), whose expression level was similar to control lungs. E13: control vs. adria EA-TEF *P < 0.001; control vs. adria noEA *P < 0.01; adria EA-TEF vs. adria noEA *P < 0.001 (control (n = 3): 1.976 ± 0.136; adria EA-TEF (n = 3): 0.834 ± 0.125; adria noEA (n = 3): 3.130 ± 0.367); E15 (black bars): control vs. adria EA-TEF *P < 0.01; control vs. adria noEA *P = 0.01; adria EA-TEF vs. adria noEA P value is not significant (control (n = 13): 1.035 ± 0.262; adria EA-TEF (n = 9): 1.463 ± 0.3; adria noEA (n = 13): 1.519 ± 0.416); E18 (gray bars): control vs. adria EA-TEF *P = 0.02; control vs. adria noEA *P = 0.02; adria EA-TEF vs. adria noEA P value is not significant (control (n = 10): 1.039 ± 0.284; adria EA-TEF (n = 11): 1.424 ± 0.438; adria noEA (n = 10): 1.437 ± 0.442); E21: control vs. adria EA-TEF *P = 0.04; control vs. adria noEA P value is not significant; adria EA-TEF vs. adria noEA P value is not significant (control (n = 12): 1.034 ± 0.263; adria EA-TEF (n = 12): 1.474 ± 0.513; adria noEA (n = 11): 1.184 ± 0.420).
Shh mRNA expression (arbitrary units) The lungs from the adria EA-TEF group of fetuses significantly overexpressed Shh, Ptch, Smo, Gli2, and Gli3 mRNA, and so did fetuses from the adria noEA group with the exception of Gli3 levels that were similar to control.
E18 (Canalicular Stage)
A significant upregulation of all the components of the Shh signaling cascade was demonstrated in the lungs of adria EA-TEF fetuses. In contrast, in the adria noEA group only the expression of Shh mRNA was significantly upregulated. Gli3 mRNA levels were significantly lower than controls. When comparing the lungs of both adriamycin-exposed groups, the levels of Ptch, Smo, and Gli2 were significantly higher in animals with EA-TEF than in those without it.
E21 (Saccular Stage)
Near the end of gestation, the lungs of adria EA-TEF fetuses expressed significantly higher levels of every Shh signaling cascade player and so did the lungs of the adria noEA fetuses, with the exception of Shh mRNA whose levels were similar to those of controls.
Immunofluorescence Distribution
The lungs from control, adria EA-TEF, and adria noEA groups were at the same stage of lung development at the specific time endpoints selected. Clear immunoreactivity was detected for Shh, Ptch, Smo, Gli2, and Gli3 at the pseudoglandular (E15), canalicular (E18), and saccular stages (E21) of lung development. All antibodies were mainly expressed in the epithelium, although Smo, Gli2, and Gli3 also exhibited disperse immunoreactivity throughout the surrounding mesenchyme.
Lungs From Control Fetuses
All the studied proteins were detected at the three stages of lung development with a predominantly epithelial immunolocalization (Figures 7-9 ).
Lungs From Fetuses Exposed to Adriamycin With EA-TEF
At the three time endpoints selected, E15, E18, and E21, these lungs appeared to express increased epithelial immunoreactivity for Shh and its downstream components. The epithelial and mesenchymal localization were similar to those of control lungs (Figures 7-9) . Ptch mRNA expression at the late embryonic, pseudoglandular, canalicular, and saccular stages of lung development. At the embryonic stage of lung development (E13, white bars), lungs from adriamycinexposed with EA-TEF (esophageal atresia and tracheoesophageal fistula) showed significantly lower levels of Ptch mRNA expression. From E13 onwards, a consistent overexpression in both adriamycin-exposed lungs was observed with the exception of adria noEA at E18 (gray bars), whose expression level was similar to control lungs. E13: control vs. adria EA-TEF *P < 0.01; control vs. adria noEA P value is not significant; adria EA-TEF vs. adria noEA *P = 0.04 (control (n = 3): 1.621 ± 0.234; adria EA-TEF (n = 3): 0.785 ± 0.056; adria noEA (n = 3): 1.999 ± 0.748); E15 (black bars): control vs. adria EA-TEF *P = 0.01; control vs. adria noEA *P < 0.01; adria EA-TEF vs. adria noEA P value is not significant (control (n = 13): 1.016 ± 0.187; adria EA-TEF (n = 9): 1.249 ± 0.227; adria noEA (n = 13): 1.252 ± 0.168); E18: control vs. adria EA-TEF *P = 0.04; control vs. adria noEA P value is not significant; adria EA-TEF vs. adria noEA *P = 0.01 (control (n = 10): 1.019 ± 0.146; adria EA-TEF (n = 10): 1.195 ± 0.207; adria noEA (n = 9): 0.893 ± 0.256); E21 (hatched bars): control vs. adria EA-TEF *P = 0.03; control vs. adria noEA *P = 0.02; adria EA-TEF vs. adria noEA P value is not significant (control (n = 12): 1.010 ± 0.354; adria EA-TEF (n = 13): 1.466 ± 0.607; adria noEA (n = 11): 1.325 ± 0.268). 
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Lungs From Fetuses Exposed to Adriamycin Without EA-TEF
At E15, immunoreactivity for Shh, Ptch, Smo, and Gli2 was apparently similar in the lungs of these fetuses and those with EA-TEF. Gli3 protein was less visible in the mesenchyme, as in control lungs. At E18, immunoreactivity for Shh was increased as in the lungs of fetuses with EA-TEF whereas Gli3 seemed decreased; Ptch, Smo, and Gli2 remained in levels comparable to those of the control group. At E21, all but Shh proteins were slightly overexpressed in adria noEA lungs (Figures 7-9 ).
DISCUSSION Lung development has a broad impact in the practice of pediatricians and pediatric surgeons involved in the treatment of children with congenital lung malformations, congenital diaphragmatic hernia, esophageal atresia, and tracheoesophageal fistula that are often accompanied by lung hypoplasia and/or prematurity or followed by chronic respiratory morbidity. It was recently reported that rat fetuses with esophageal atresia and tracheoesophageal fistula induced by adriamycin have hypoplastic lungs and abnormal control of branching with FGF10 (fibroblast growth factor 10) overexpression in the pseudoglandular, canalicular, and saccular stage of lung development (22, 23) .
In adriamycin-exposed embryos, the emergence of the respiratory component is abnormal because the esophagotracheal foregut tube fails to divide (24) . The abnormal emergence of the lung bud at E12 seems to affect lung growth. In fact, our results revealed that at the embryonic stage of lung development (E13) in the adriamycin-exposed embryos the lungs are smaller than controls with those with EA-TEF showing the most marked reduction of lung mass and downregulation of the Shh pathway, suggesting a previously defective Shh environment in the adriamycin-exposed embryos further exacerbated by the malformation itself. From the pseudoglandular stage onwards, a remarkable switch in Shh expression levels and its downstream pathway components takes place and a consistent overexpression of Shh, Ptch, Smo, Gli2, and Gli3 mRNA was observed in comparison to the control lungs. It suggests the presence of an intrinsic mechanism pointing to recovery of normal growth since Shh overexpression in the developing lung leads to enhanced epithelial and mesenchymal cell proliferation (25) . An interesting finding in the adriamycin-exposed rats without EA-TEF was that Shh signaling pathway levels of expression Figure 5 . Gli2 mRNA expression at the late embryonic, pseudoglandular, canalicular, and saccular stages of lung development. Adria EA-TEF (esophageal atresia and tracheoesophageal fistula) lungs showed a significantly lower level of Gli2 mRNA in contrast to the highest level expressed by the adria noEA group at the late embryonic stage of development (white bars). Once more, from E13 onwards consistent higher levels of Gli2 mRNA expression were observed in both adriamycin-exposed lungs except for the adria noEA group at E18 (gray bars). E13: control vs. adria EA-TEF *P = 0.04; control vs. adria noEA *P = 0.02; adria EA-TEF vs. adria noEA *P < 0.01 (control (n = 3): 1.761 ± 0.271; adria EA-TEF (n = 3): 1.2 ± 0.213; adria noEA (n = 3): 2.525 ± 0.286); E15 (black bars): control vs. adria EA-TEF *P = 0.04; control vs. adria noEA *P = 0.03; adria EA-TEF vs. adria noEA P value is not significant (control (n = 9): 0.985 ± 0.142; adria EA-TEF (n = 9): 1.322 ± 0.319; adria noEA (n = 8): 1.169 ± 0.186); E18: control vs. adria EA-TEF *P = 0.001; control vs. adria noEA P value is not significant; adria EA-TEF vs. adria noEA *P < 0.001 (control (n = 9): 1.014 ± 0.204; adria EA-TEF (n = 7): 1.553 ± 0.330; adria noEA (n = 9): 0.865 ± 0.295); E21 (hatched bars): control vs. adria EA-TEF *P = 0.01; control vs. adria noEA *P < 0.01; adria EA-TEF vs. adria noEA P value is not significant (control (n = 9): 0.785 ± 0.180; adria EA-TEF (n = 10): 1.155 ± 0.335; adria noEA (n = 10): 1.148 ± 0.299). . Gli3 mRNA expression at the late embryonic, pseudoglandular, canalicular, and saccular stages of lung development. At the earliest studied stage of lung development (E13, white bars), Gli3 mRNA was underexpressed by adria EA-TEF (esophageal atresia and tracheoesophageal fistula) lungs in contrast to the overexpression observed in the adria noEA group. From E13 onwards, both adriamycin-exposed lungs showed significantly higher levels of expression with the exception of adria noEA at E15 (black bars), whose expression level was similar to control lungs. E13: control vs. adria EA-TEF *P < 0.01; control vs. adria noEA *P = 0.01; adria EA-TEF vs. adria noEA *P = 0.001 (control (n = 3): 1.785 ± 0.122; adria EA-TEF (n = 3): 1.198 ± 0.150; adria noEA (n = 3): 4.408 ± 0.685); E15: control vs. adria EA-TEF *P = 0.01; control vs. adria noEA P value is not significant; adria EA-TEF vs. adria noEA P value is not significant (control (n = 9): 0.972 ± 0.295; adria EA-TEF (n = 8): 1.430 ± 0.405; adria noEA (n = 9): 1.109 ± 0.216); E18 (gray bars): control vs. adria EA-TEF *P = 0.02; control vs. adria noEA *P < 0.01; adria EA-TEF vs. adria noEA *P < 0.0001 (control (n = 10): 1.096 ± 0.329; adria EA-TEF (n = 8): 1.556 ± 0.481; adria noEA (n = 9): 0.551 ± 0.148); E21 (hatched bars): control vs. adria EA-TEF *P = 0.01; control vs. adria noEA *P = 0.04; adria EA-TEF vs. adria noEA P value is not significant (control (n = 9): 0.817 ± 0.228; adria EA-TEF (n = 11): 1.220 ± 0.406; adria noEA (n = 10): 1.096 ± 0.323). 
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were somewhat different from those in the lungs of rats with EA-TEF. In fact, at E13 the expressions of Shh, Smo, Gli2, and Gli3 mRNA were higher than controls and much higher than in lungs of adria EA-TEF rats whereas Ptch showed similar levels of mRNA to the control group. Nevertheless, at the pseudoglandular stage, the expression levels of Shh, Ptch, Smo, and Gli2 were significantly higher than controls and similar to the adria EA-TEF lungs. It is interesting to point out that in the adriamycin-exposed embryos without EA-TEF, despite the upregulation of Shh until E18, there was a trend to reduce and Articles Fragoso et al.
normalize the expression throughout gestation. Furthermore, "erratic" behavior of the signaling pathway in these lungs suggests a disturbed pathway in some way different from the adria EA-TEF lungs eventually responsible for the different embryo phenotype induced by adriamycin administration (with or without EA-TEF). In addition, the putative effect of the tracheoesophageal fistula in lung organogenesis and growth must be considered, because Shh expression is also stimulated by physical pressures (26) (27) (28) , and the disturbed swallowing plus the gastrointestinal obstruction seen in EA may perturb the lung dynamics exceptionally important for lung development. In summary, and despite the absence of a semiquantitative protein assessment not allowing a discussion based on functional protein contents, immunofluorescence results seemed to be consistent with the real-time RT-PCR results. Both groups exposed to adriamycin showed a disturbed Shh signaling by real-time RT-PCR quantification. However, at the embryonic stage of lung development they expressed clear differences in mRNA levels of Shh and its downstream components. In fact, in adria EA-TEF lungs, Shh is downregulated whereas in adria noEA lungs it is upregulated. This corroborates previous findings stating that a specific temporal expression of Shh is determinant for normal foregut and lung development. Shh disturbance induced by adriamycin is crucial for the development of EA-TEF, but seems to depend on gene gradient/dosage and other precise spatial and temporal interactions that would explain why only about 70% of rat fetuses from mothers exposed to adriamycin have EA-TEF (29) .
Despite the major foregut anomalies seen in patients with EA-TEF/VACTERL association, the lung is, in general, grossly normal. However, up to 75% of EA-TEF patients suffer from chronic respiratory symptoms and spirometric abnormalities apparently not related to gastroesophageal reflux, prematurity, or other EA-TEF sequelae (30) . This may be explained by a deficient prenatal signaling, because there is increasing evidence that several signaling pathways important in prenatal development continue to have vital roles in adult life, namely in coordinating an appropriate response to injury (31) .
In conclusion, our results demonstrate abnormal Shh pathway gene expression in adriamycin-exposed embryos since the embryonic stage of lung development may be due to the disturbed Shh environment previously described in the foregut of 
